高盛:下调Bristol-Myers Squibb(BMY.US)评级,由买入调整至中性评级,目标价由67.00美元调整至55.00美元。施贵宝(BMY.US)公司简介:百时美施贵宝公司从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。它提供化学合成药物或小分子和生物过程产生的产品,称为生物制剂。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.